12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ambrisentan: Development discontinued

Gilead discontinued development of ambrisentan to treat IPF after an interim analysis of unblinded safety and efficacy data from the double-blind, placebo-controlled, international Phase III ARTEMIS-IPF trial showed no evidence of a treatment benefit. The company said more than 70% of a planned...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >